299 related articles for article (PubMed ID: 31488221)
1. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
Gunjur A; Klein O; Kee D; Cebon J
J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
[TBL] [Abstract][Full Text] [Related]
2. Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: a case report and review of the literature.
Pan Q; Li P
Front Immunol; 2024; 15():1366335. PubMed ID: 38707904
[TBL] [Abstract][Full Text] [Related]
3. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
4. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
6. [Two cases of granuloma annulare under anti-PD1 therapy].
Charollais R; Aubin F; Roche-Kubler B; Puzenat E
Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
[TBL] [Abstract][Full Text] [Related]
7. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
Amode R; Baroudjian B; Kowal A; Jebali M; Allayous C; Bagot M; Madjlessi N; Roux J; Viguier M; Basset Seguin N; Porcher R; Pagès C; Lebbé C
Melanoma Res; 2017 Apr; 27(2):110-115. PubMed ID: 27926587
[TBL] [Abstract][Full Text] [Related]
8. ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management.
Shi Y; Shen M; Zheng X; Chen Y; Zhao R; Gu Y; Yang T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32905579
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
12. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
Tsang VHM; McGrath RT; Clifton-Bligh RJ; Scolyer RA; Jakrot V; Guminski AD; Long GV; Menzies AM
J Clin Endocrinol Metab; 2019 Nov; 104(11):5499-5506. PubMed ID: 31265074
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab use for the treatment of advanced melanoma.
Specenier P
Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
[TBL] [Abstract][Full Text] [Related]
15. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
16. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
18. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
19. Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
Hoadley A; Sandanayake N; Long GV
Ann Oncol; 2017 Feb; 28(2):434-435. PubMed ID: 27864215
[No Abstract] [Full Text] [Related]
20. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
